會員登入
註冊
GlobalBio Monthly Volume 123 Is Here!
As 2024, the Year of the Dragon, draws to a close, we prepare to welcome 2025, the Year of the Snake!
Highlights of 2024: The Biotech Industry Shines
In 2024, the global biotech and pharmaceutical sectors experienced remarkable advancements and challenges:
- Generative AI reshaped the pharmaceutical landscape, accelerating drug discovery and innovation.
- The rise of breakthrough obesity treatments captured global attention.
- Approvals for advanced therapies surged, driving innovation in modalities like cell and gene therapies.
- Meanwhile, U.S. drug pricing reforms stirred the generics and biosimilars market.
Achievements in Taiwan's Biotech Sector:
- 16 new drug approvals across generics, biologics, traditional Chinese medicine, and antibiotics.
- 12 successful clinical trial readouts from mid to late-stage trials, showcasing their diversity and resilience.
Despite a prolonged downturn in the global capital market, initial public offerings (IPO) activity in biotech fell worldwide. Yet, Taiwan defied the trend with a biotech IPO boom, welcoming 36 new companies to the stock exchange.
This issue takes you on a journey:
- A review of Taiwan's outstanding biotech achievements in 2024.
- Insights into the 10 milestones of cell and gene therapies approved by the U.S. FDA in 2024.
- An introduction to 10 rising CRISPR scientists, offering a glimpse into the next decade of gene-editing advancements.
Biotech Opportunities in 2025: What's Next?
What will be the next major biotech breakthrough as we look ahead to 2025?
Read the full issue: Explore Now
